semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer All tumors must be ER-, PR and HER2-negative Clinical stage T2 or T3, N0-3, M0. Subjects with inflammatory breast cancer are not eligible For subjects with clinically negative axilla, a sentinel lymph node biopsy will be performed either up front or after preoperative therapy at the discretion of the subject's physicians; for subjects with a clinically positive axilla, a needle aspiration or core biopsy will be performed to confirm the presence of metastatic disease in the lymph nodes years of age or older Performance status (PS) of 0 or 1 Use of an effective means of contraception in subjects of child-bearing potential Normal organ function as described in the protocol  Any prior cytotoxic chemotherapy or radiation for the current breast cancer HER2-negative ipsilateral breast recurrence, unless prior treatment consisted of excision alone for ductal carcinoma in situ (DCIS)or breast-conserving treatment and hormonal therapy for DCIS or invasive cancer Life expectancy of less than 12 weeks Current, recent, or planned participation in an experimental durg study other than a Genentech-sponsored bevacizumab cancer study Renal dysfunction for which exposure to cisplatin would require dose modifications Steroid dependent asthma Peripheral neuropathy of any etiology that exceeds grade 1 Uncontrolled diabetes History of malignancy treated without curative intent Any other pre-existing medical condition that would represent toxicity in excess of grade 1
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Breast Cancer Patient with unifocal histologically proven breast cancer, with or without calcifications in mammogram DCIS (Ductal carcinoma in situ) (Tis, Stage 0) Non-lobular infiltrating carcinoma, maximum of 2 cm in diameter. (T1, Stage I) The patient was operated on and the tumor was excised with lumpectomy The tumor is reported with negative margins >3 mm, as per our hospital protocol For invasive carcinoma, axillary lymph nodes are negative by sentinel lymph node (SLN) mapping and biopsy or by formal axillary lymph node dissection The patient is over 40 years old with life expectancy of at least 5 years Karnofsky status must be at least 70. See appendix I Pre and post-menopausal women are eligible for entry  No concurrent or neoadjuvant chemotherapy is allowed. Patient is permitted to be treated with chemotherapy or hormone therapy only after completion of the radiation treatment Patients with diffuse calcifications, multifocal or multicentric disease, lymph-vascular invasion are excluded Patients cannot participate if there is extensive LCIS (Lobular carcinoma in situ) in specimen or extensive DCIS Patients are excluded if systemic disease is present or the patient has been irradiated to the ipsilateral breast or the chest wall Patients who are carriers of BRCA 1/2 mutations or at high risk for hereditary breast cancer due to strong family history (more than one pre-menopausal family member with breast cancer or any ovarian cancer) are excluded because of the increased potential for in-breast recurrence elsewhere in the breast in the absence of whole breast radiotherapy Patients with scleroderma, or systemic or discoid lupus are excluded due to the potential for significant radiotherapy associated toxicity Pregnant woman cannot participate in the study Patients who have serious medical problems which would limit survival to <5 years or a psychiatric condition which would prevent informed consent cannot participate Patients who are unable to lie on their back and raise their arms above their heads in the treatment planning position for radiotherapy are excluded Patients that have mammographically occult disease are excluded
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-120.0,  Breast Cancer Long-term Effects Secondary to Cancer Therapy in Adults Skin Reactions Secondary to Radiation Therapy Women who have chosen to undergo breast conservation therapy, including lumpectomy and breast irradiation, at the University of Pennsylvania for any invasive mammary carcinoma or intraductal breast cancer Stage I-II invasive or intraductal breast cancer Unifocal tumor ≤ 3.0 cm in size Patients with microscopic multifocality are eligible provided total pathologic tumor size is ≤ 3 cm No proven multicentric carcinoma in more than 1 quadrant or separated by 4 or more centimeters Pre or post-biopsy ipsilateral* breast MRI negative for multicentric disease (i.e., areas of cancer that cannot be removed in a single excision specimen) or other suspicious findings NOTE: *Patients with synchronous bilateral breast cancers who will be treated with radiotherapy to each breast are eligible, provided such treatment can be performed in a manner that avoids overlap between treatment fields. Both sides may be treated with partial breast irradiation (PBI) if the pathologic are met for both tumors, or only one side may be treated with PBI if the are met for only one tumor Negative margins of excision (≥ 2 mm) OR no tumor seen in a re-excision specimen No extensive intraductal component present Negative sentinel lymph node (SLN) or axillary lymph node dissection OR fewer than 4 positive nodes on adequate axillary lymph node dissection (i.e., 10 or more lymph nodes removed)
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Breast Cancer Histologically confirmed primary invasive breast carcinoma Stage I-IIA disease (T1, N0, M0 or T2, N0, M0) Pathologically determined single, discrete, and well-defined primary tumor ≤ 5 cm in diameter Pathologically negative surgical margins No multicentric disease and/or diffuse malignant appearing microcalcifications Micro-calcifications must be focal Specimen radiograph is required after lumpectomy for tumors associated with malignant appearing calcifications to assure removal of all malignant appearing calcifications Specimen radiograph is optional if the tumor appears as a discrete mass on mammogram No axillary lymph node involvement No evidence of metastatic breast cancer
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Biopsy-confirmed invasive ductal carcinoma of the breast Unifocal disease as defined by clinical examination, mammography, and ultrasound Patient must be proceeding to mastectomy Hormone receptor status unknown No T4d or multifocal disease (as defined on conventional imaging) Index tumor ≤ 4 cm in diameter Menopausal status not specified Female No claustrophobia No cup size of DD or greater PRIOR
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 25.0-999.0,  Breast Cancer Individuals aged 25 years or older Individuals who have at least one breast imaging finding requiring biopsy, specifically Individuals who have a breast abnormality(ies) moderately suspicious for or highly suggestive of malignancy on imaging with mammography, ultrasound, or MRI (as per ACR 4C or 5) and requiring biopsy confirmation OR o Individuals with known breast cancer who have additional imaging abnormality(ies) suspicious for malignancy detected on a high-resolution FDG PET scan Individuals who had recent conventional imaging work-up including x-ray mammography of the breast containing the abnormality of interest Individuals with suspected tumor size measuring one cm or less on mammography and/or ultrasound and/or MRI if the lesion is visible on any of these modalities, except that each site may enroll up to three patients each where the lesion of interest as measured on mammography (or ultrasound and/or MRI if not detectable on mammography) is more than 1 cm. (Note: The study will target patient enrollment such that at least 50% of the lesions to undergo biopsy across all sites will be less than 1 cm in diameter as measured on mammography, or as measured by other modalities, such as ultrasound, CT, or MRI, if the lesion is not detectable or measurable on mammography.) Individuals who have agreed to participate in the study and who have signed study-specific informed consent  Women who are or may be pregnant Women who are currently lactating or discontinued breastfeeding < 2 months prior to the study Age less than 25 years Individuals with breast implant(s) in the breast containing the lesion of interest Individuals who are scheduled for a sentinel node procedure using radioactive Tc-99m within 24 hours of PET-guided biopsy Patients with contraindications for core biopsy and other invasive procedures such as blood coagulation disorders, infection, or who are unwilling to discontinue use of anticoagulant medication prior to the procedure Individuals with Type I or poorly controlled Type II diabetes mellitus Individuals with a blood glucose level that is above 140 mg/dl at the time of PEM imaging Inability to provide informed consent Individuals who have had surgery on the study breast(s) within the past 12 months
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-120.0,  Breast Cancer Participant in the Mayo Mammography Health Study Has consented to provide baseline mammogram for digitization ECOG performance status 0-1 Female Postmenopausal (defined as women who have had both ovaries removed or no menstrual period for at least 12 consecutive months) Able to give informed consent and complete food records alone or with assistance Willing to provide research blood and urine samples Must be a non-smoker Willing to maintain current weight No history of breast ductal carcinoma in situ or any other cancer, except basal cell or squamous cell skin cancer or lobular carcinoma in situ
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Breast Cancer Women with histologically-confirmed unilateral invasive ductal or lobular breast adenocarcinoma HER2/c-neu over expression should be documented by either immunohistochemistry (score 3+) or FISH/CISH positivity. A score of 2+ by immunohistochemistry is acceptable only if FISH/CISH positive Within 60 days after the surgical excision of the primary tumor with tumor-free operation margins; at least 10 axillary lymph nodes have to be removed Tumor involvement of at least one axillary lymph node (N0 with HER2/c-neu over expression are also eligible) Absence of any clinical or radiological evidence of local or metastatic disease Premenopausal or postmenopausal women aged 18-75 years old Adequate bone marrow function (absolute neutrophil count >1500/mm3, platelet count >100.000/mm3, hemoglobin >10gr/mm3) Adequate liver (bilirubin <1.0 times upper limit of normal and SGOT/SGPT <2.5 times upper limit of normal) and renal function (creatinine <1.5mg/dl) Adequate cardiac function (LVEF>50%). Normal electrocardiogram and absence of significant heart disease Written informed consent  Positive pregnancy test Psychiatric illness or social situation that would preclude study compliance Other concurrent uncontrolled illness Prior or concurrent antineoplastic therapy e.g. hormonal therapy, radiation therapy, chemotherapy, biological agents Previous history of other invasive malignancy other than non-melanomatous skin cancer
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 21.0-90.0,  Breast Cancer HER2-negative Breast Cancer HER2-positive Breast Cancer Recurrent Breast Cancer Stage IA Breast Cancer Stage IB Breast Cancer Stage II Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Patients must be women with a histologically confirmed diagnosis of breast cancer that is more than 1 cm and or lymph node positive Physical examination, and scans needed for tumor assessment must be performed within 90 days prior to registration Patients with the clinical diagnosis of congestive heart failure or angina pectoris are NOT eligible Serum creatinine within normal limits within 90 days prior to registration Bilirubin within normal limits within 90 days prior to registration Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) =< 2 x the institutional upper limit of normal within 90 days prior to registration Absolute neutrophil count (ANC) of >= 1,500/microliters within 90 days prior to registration Platelet count of >= 100,000/microliters within 90 days prior to registration Patients must have a performance status of 0-2 by Zubrod Pregnant or nursing women may not participate; women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method; pregnancy test required for women of childbearing potential
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Atypical Lobular Hyperplasia Atypical Ductal Hyperplasia Lobular Carcinoma in Situ for Surveillance Arm Diagnosis of biopsy-prove ADH, ALH, or LCIS within the past 5 years based on core needle biopsy and/or excisional biopsy and confirmed by a Mayo pathologist. for Diagnostic Arm Recent core needle biopsy of the breast demonstrating ADH, ALH, or LCIS confirmed by Mayo pathologist  They are unable to understand and sign the consent form They are pregnant or lactating They are physically unable to sit upright and still for 40 minutes They are younger than 18 years of age
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Histologically proven invasive unilateral breast cancer (regardless of the type) Initial clinical condition compatible with complete initial resection No residual macro or microscopic tumor after surgical excision Node-positive disease (i.e., positive sentinel node or positive axillary clearance) (N+) or node-negative disease (-) meeting the following  Stage II or III disease pT >20 mm (T1-4) Patients must meet 1 of the following hormone-receptor Node-positive patients: triple-negative* tumor (HER2 negative, estrogen-receptor [ER] negative, and progesterone receptor [PR] negative) OR double-negative (HER2 negative, PR negative, and ER+) Node-negative patients: triple-negative* tumor only NOTE: *Hormone-receptor negativity is defined as ER <10% and PR <10% by IHC and HER2 negativity is defined as IHC 0-1+ OR IHC 2+ and FISH or CISH negative  Clinically or radiologically detectable metastases (M0) Bilateral breast cancer or contralateral ductal carcinoma in situ Any metastatic impairment, including homolateral subclavicular node involvement, regardless of its type Any tumor ≥T4a (cutaneous invasion, deep adherence, inflammatory breast cancer) HER 2 overexpression defined as IHC 3+ OR IHC 2+ and FISH or CISH positive Any clinically or radiologically suspect and non-explored damage to the contralateral breast Female Pre or postmenopausal ECOG performance status 0-1